New eye drop aims to zap pink eye germs

NCT ID NCT07565103

Recruiting now Disease control Sponsor: Senju USA, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This trial tests a new antibiotic eye drop called SUM-191 for bacterial conjunctivitis (pink eye). It has three parts: first, healthy volunteers get a single dose to check safety; second, healthy volunteers get multiple doses for 6 days; third, patients with pink eye get the drops for 6 days to see if it clears the infection. The study involves 426 people and is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SUM-191 eye drops

What this could lead to

If successful, this could lead to a new antibiotic eye drop treatment for bacterial conjunctivitis (pink eye).

What could go wrong

This is an early phase I/II trial, so safety and effectiveness are not yet proven. The study is small and not yet recruiting, so results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates